IMDX

Insight Molecular DiagnosticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

Current thesis

A first-mover FDA authorization for a kitted dd-cfDNA transplant assay could shift IMDX from development story to commercial platform, with February financing reducing immediate balance-sheet stress and management highlighting growing transplant-center engagement [#10-K-2026-03-26] [#PR-2026-03-26].

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.0.

What can break

Cash runway improved after the February 2026 raise, but losses remain heavy and future financing risk is not eliminated.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $3.20 · Bull $5.80 · Bear $2.00

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net Neutral

Target $8.33

Why

Momentum12 · Δ7d +8.7

Value41 · Δ7d +0.0

Sentiment19 · Δ7d +3.2

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+8.7

Δ21d

-31.6

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+3.2

Δ21d

+7.7

Why this grade

Composite grade F. Momentum 12.5 / Value 41.1 / Sentiment 19.1

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$156.29M

Beta

1.35

Shares Out

32.29M

P/E (TTM) · Derived

-2.9

P/S (TTM)

48.64

P/FCF (TTM) · Derived

-5.77

Rev YoY

-98.5%

EPS YoY

-52.1%

Gross Margin

-64.9%

Op Margin

-1392.9%

Net Debt

-$8.82M

Current Ratio

2.54

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology